COMMODORE CAPITAL LP
COMMODORE CAPITAL LP's purchase track record
How the stock did after each of COMMODORE CAPITAL LP's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/7/2023 | VTGN | $17.96M | -74.0% | -64.8% | +9.4% |
| 6/20/2023 | VERA | $6.80M | +10.0% | +6.3% | +8.6% |
| 2/21/2023 | ELVN | $177K | -7.9% | -20.0% | +9.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
VTGN linked to growing vasomotor symptoms market amid recent price dip. The vasomotor symptoms market is projected to expand through 2036 as adoption of hormonal and non‑hormonal therapies rises, a trend that aligns with VTGN’s focus on treatments for menopausal symptoms. At the same time, VTGN appeared on a recent list of falling stocks that traders are watching, indicating recent price weakness. These factors together provide context for the stock’s current market environment.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Enliven's ENABLE-2 Trial Design Sparks New Questions. Enliven Therapeutics has clarified the design of its ENABLE-2 Phase 3 trial for relcobatinib in chronic myeloid leukemia, following questions raised by the trial’s structure. The company also confirmed FDA alignment on the study, while a separate patent dispute involving Halozyme and Merck has kept the leukemia treatment landscape in focus. These developments highlight the regulatory and strategic challenges Enliven faces as it moves toward clinical milestones.
Transaction History
| VERA | ▼ Sell | Open Market | 1,050,000 | $18.9M | 1/10/2024 | View on chart |
| VTGN | ▲ Buy | Open Market | 775,756 | $18.0M | 8/7/2023 | View on chart |
| VERA | ▲ Buy | Open Market | 448,217 | $6.8M | 6/20/2023 | View on chart |
| ELVN | ▼ Sell | Other | 729,891 | — | 2/23/2023 | View on chart |
| ELVN | ▲ Buy | Open Market | 622 | $14K | 2/23/2023 | View on chart |
| ELVN | ▲ Buy | Open Market | 23,565 | $120K | 2/22/2023 | View on chart |
| ELVN | ▲ Buy | Open Market | 8,194 | $43K | 2/21/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Leerink Partners Covers Vera Therapeutics at $34 Target
Leerink Partners has started coverage of Vera Therapeutics, giving it a Market Perform rating and a price target of $34. The target sits near the lower end of the company’s 52‑week range and close to the current support level of $33.79. The new rating may influence how traders view the stock’s short‑term prospects. The RSI of 37 suggests the stock is not overbought or oversold at this time.
Leerink Partners Covers Vera Therapeutics at $34 Target. Leerink Partners has started coverage of Vera Therapeutics, giving it a Market Perform rating and a price target of $34. The target sits near the lower end of the company’s 52‑week range and close to the current support level of $33.79. The new rating may influence how traders view the stock’s short‑term prospects. The RSI of 37 suggests the stock is not overbought or oversold at this time.